Precipio Inc
Precipio Inc (PRPO) is a small-cap healthcare company operating in the diagnostics and specialised laboratory services space, with a market capitalisation of about $35.1 million. The business focuses on diagnostic tools and laboratory solutions used in oncology and haematology, aiming to improve disease detection and diagnostic accuracy. For investors, key considerations include its niche market position, the capital intensity of clinical and laboratory operations, and the potential for volatile share price moves typical of micro-cap stocks. Financial performance may hinge on test adoption, reimbursement dynamics, regulatory milestones and any strategic partnerships. Given its size, liquidity can be limited and business outcomes may be binary around product or regulatory developments. This summary is for general educational purposes only and not personalised investment advice. Stocks like PRPO are higher risk and may not suit all investors; consider diversification, your risk tolerance and consult a regulated financial adviser before investing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Precipio's stock with a target price of $19, indicating strong growth potential.
Financial Health
Precipio Inc shows modest revenue and cash flow, but its profitability is somewhat limited.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PRPO
Liquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Niche diagnostic focus
Precipio targets oncology and haematology diagnostics, a specialised area where clinical adoption can drive growth — though adoption and reimbursement can be uncertain.
Small‑cap volatility
With a market cap around $35M, PRPO can be highly volatile and illiquid; price swings may be large and outcomes binary around milestones.
Regulation and partnerships
Regulatory approvals and strategic partnerships can materially affect prospects, so investors often monitor clinical, regulatory and commercial updates closely.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
